Moderna nears US authorisation for Covid-19 shot with FDA staff endorsement | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
The Business Standard

Monday
October 02, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
MONDAY, OCTOBER 02, 2023
Moderna nears US authorisation for Covid-19 shot with FDA staff endorsement

Coronavirus chronicle

Reuters
15 December, 2020, 07:55 pm
Last modified: 15 December, 2020, 10:36 pm

Related News

  • Acme's muscle relaxant tablet 'Chlorzoxazone 500' gets US FDA approval
  • US FDA says India-made eye drop linked to some infections, blindness and one death
  • Variant-adapted Covid vaccine wins first approval in Britain
  • US FDA authorizes Novavax Covid vaccine for adults
  • US approves first pill for treatment of alopecia

Moderna nears US authorisation for Covid-19 shot with FDA staff endorsement

The FDA reviewers said a two-dose regimen of Moderna's vaccine was highly effective in preventing confirmed cases of Covid-19 and did not raise any specific safety issues with using the vaccine in adults over the age of 18

Reuters
15 December, 2020, 07:55 pm
Last modified: 15 December, 2020, 10:36 pm
Moderna nears US authorisation for Covid-19 shot with FDA staff endorsement

Moderna Inc's Covid-19 vaccine appeared set for regulatory authorization this week after US Food and Drug Administration staff endorsed it as safe and effective in documents released Tuesday.

The coronavirus pandemic has killed more than 300,000 people in the US and the government is counting on the Moderna shot to help fulfill its promise to inoculate 20 million this month.

An FDA decision on whether to issue a so-called emergency use authorization for the Moderna vaccine will be made after a panel of outside advisers meets Thursday. The FDA typically follows the advice of the panel, but is not required to do so.

Moderna's is the second vaccine the FDA has considered, behind one from Pfizer Inc. and Germany's BioNTech , which was authorized last week. Hospitals in the US began giving the Pfizer shots on Monday.

The New York Times, citing unnamed sources, reported that the FDA decision on Moderna's vaccine would be on Friday. FDA did not immediately respond to a request for comment on the NYT report.

FDA staff said in documents prepared for that meeting that a two-dose regimen of Moderna's vaccine was highly effective in preventing confirmed cases of Covid-19 and did not raise any specific safety issues in adults over the age of 18.

Moderna released data in documents supporting previous statements that the vaccine may prevent some asymptomatic infections of Covid-19.

It said 38 trial participants in the placebo arm of its trial tested positive for Covid-19 without exhibiting symptoms at the time of their second dose - nearly triple the number in the vaccine arm of the trial.

Both Moderna and Pfizer designed their late-stage trials to show that their vaccines were capable of preventing more significant forms of Covid-19, in the hope that the shots could prevent hospitalizations and deaths.

But preventing asymptomatic infection is also important and could reduce the chances of vaccinated people infecting the unvaccinated, further stemming the spread of the disease.

ONE SHOT SUCCESS?

The FDA said that there appeared to be some protection for trial participants after the first dose of Moderna's vaccine, which is given in two shots, with 28 days between inoculations, but there was not enough information on longer term protection.

It said that vaccine efficacy was 80.2% in participants who only received one dose at the time of the interim analysis, which was based on data collected as of Nov. 7.

But the FDA said it could not draw a conclusion because the numbers of participants and time of observation were limited and there was no single-dose arm in the 30,000 person trial.

Moderna said trial participants, half of whom received a placebo, may request to find out if they had a placebo or the vaccine so that they can get either the vaccine or another vaccine potentially available outside of the trial.

The FDA staff said that serious side effects in the trial of the vaccine represented medical events that occur in the general population at a similar frequency as observed in the study.

The FDA did flag the possibility that the vaccine was contributing to Bell's palsy, a type of facial paralysis also reported by participants in the Pfizer trial.

Moderna reported four cases of Bell's palsy, including three among people who had the vaccine and 1 in the placebo group. The company said that three of the cases had resolved itself.

Although the FDA said that the trial participants with Bell's palsy had predisposing factors, the "potential contribution of the vaccine to the manifestations of these events of facial palsy cannot be ruled out".

Pfizer reported six cases of Bell's palsy, including 4 in the vaccine arm, which it said was a rate typical of the general population.

Thirteen people who participated in the trial died, six who received the vaccine and seven who received the placebo.

The death rate during the trial was in line with death rates in the general population for patients of this age, the documents said. There was only one Covid-19 related death, a patient who received the placebo.

Moderna shares, which have risen nearly eight-fold this year up to Monday's close, were up 1.8% before the bell.

Top News

Moderna Covid-19 Vaccine / US FDA

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Illustration: TBS
    Why do Bangladeshi universities fare so poorly in global rankings?
  • Solar panels at a field in a rural area of Bangladesh. File Photo: Rehman Asad/TBS
    Solar soon to be the most affordable electricity source for Bangladesh: Bloomberg
  • Illustration: TBS
    Stakeholders seek NBR clarification over tax exemption on Universal Pension investment

MOST VIEWED

  • Paperfly aborts flight
    Paperfly aborts flight
  • Photo: TBS
    Habibur Rahman takes charge as 36th DMP commissioner
  • US dollar banknotes are seen in this illustration taken on 10 March 2023. Photo: Reuters
    Remittance earnings in September lowest in 41 months
  • How China's Belt and Road changing Bangladesh's  infrastructures
    How China's Belt and Road changing Bangladesh's infrastructures
  • Some banks get more remittance. Is it for extra efforts, or higher dollar rates?
    Some banks get more remittance. Is it for extra efforts, or higher dollar rates?
  • Representational image. Photo: Masum Billah
    Exporting mango trees to Dubai: Bangladeshi farmers tap into afforestation programmes in Gulf countries

Related News

  • Acme's muscle relaxant tablet 'Chlorzoxazone 500' gets US FDA approval
  • US FDA says India-made eye drop linked to some infections, blindness and one death
  • Variant-adapted Covid vaccine wins first approval in Britain
  • US FDA authorizes Novavax Covid vaccine for adults
  • US approves first pill for treatment of alopecia

Features

Shahjahan Bhuiyan’s parents and two out of his three siblings passed away when he was behind bars. He missed all the funerals.  
Photo: Nayem Ali

Hangman Shahjahan Bhuiyan: Life after 60 executions and 44 years in prison

3h | Panorama
Illustration: Collected

Apology to a life forgotten to live

17h | Features
Photo: Kazi Ashraf Uddin

Coffee: More than a beverage, something of a beloved

20h | Features
The price back to the normal range is possible if the corporations who control the feed market reduce the feed and chick prices. Photo: Noor-A-Alam

Will eggs ever return to their 'normal' price?

23h | Features

More Videos from TBS

How much time do you spend on mobile apps?

How much time do you spend on mobile apps?

1h | Tech Talk
Everything about the ICC Cricket World Cup 2023 stadiums: Part 1

Everything about the ICC Cricket World Cup 2023 stadiums: Part 1

15h | TBS SPORTS
Apple is bringing new software updates to prevent overheating

Apple is bringing new software updates to prevent overheating

17h | Tech Talk
A unique study cafe in the city

A unique study cafe in the city

16h | TBS Stories
EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]